Cytognos
Cytognos, S.L. is a privately held Spanish biotech that designs, manufactures, and commercializes CE-IVD standardized flow cytometry reagents, Infinicyt™ analysis software, and EuroFlow™ reference databases for oncohematology, immunology, and clinical-trial laboratories worldwide.
- Company typePrivate
- Founded1996
- HeadquartersSalamanca, Spain
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Cytognos does
Cytognos, S.L. is a privately held Spanish biotechnology company (Sociedad Limitada) founded in 1996 and headquartered in Santa Marta de Tormes, Salamanca, that designs, develops, manufactures, and commercializes standardized clinical flow cytometry solutions for oncohematology, immunology, and clinical trial laboratories. The company's portfolio is built around its Next Generation Flow (NGF)™ CE-IVD platform, which combines proprietary reagents (single antibodies, multicolor cocktails, ancillary reagents such as BulkLysis™), the Infinicyt™ analysis software (automated gating, Compass classification, maturation tools, compensation management), and the EuroFlow™ reference databases — a methodology and database set for which Cytognos holds an exclusive commercial license from the European Scientific Foundation for Laboratory Hemato Oncology (ESLHO).
The integrated product covers the full pre-analytical-to-reporting workflow for sensitive minimal residual disease (MRD) detection at sensitivity levels of 10⁻⁶, with disease-specific NGF solution lines for acute leukemia, chronic lymphoproliferative disorders, plasma cell dyscrasias (multiple myeloma), primary immunodeficiencies (PIDOT), monocyte subset monitoring (Timascan), and clinical-trial sample analysis. Validated compatibility exists with multiple cytometer platforms (BD FACSCanto II, BD FACSLyric, Omnicyt, Thermo Fisher Attune NxT), enabling instrument-agnostic deployment, and the software connects to Laboratory Information Systems (LIS) through configurable XML export.
Cytognos monetizes the platform through one-time reagent and CE-IVD kit sales, bundled database add-ons, and recurring/standalone Infinicyt software licenses (network license options available). The company operates a hybrid go-to-market combining direct sales and a large network of regional distributors spanning Europe (UK, France, Germany, Netherlands, Iberia, Nordics, CEE), LATAM (Mexico, Colombia), and the US, complemented by joint marketing with BD at major immunology congresses. Quality and regulatory posture is anchored by ISO 13485:2016, ISO 9001:2015, CE-IVD marking under EU IVDR, and US FDA 21 CFR Part 820 compliance for Analyte Specific Reagents.
Cytognos firmographics
Firmographics- Name
- Cytognos
- Legal name
- Cytognos, S.L.
- Website
- https://cytognos.com
- Company type
- Private
- Founded year
- 1996
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Cytognos, S.L. is a privately held Spanish biotech that designs, manufactures, and commercializes CE-IVD standardized flow cytometry reagents, Infinicyt™ analysis software, and EuroFlow™ reference databases for oncohematology, immunology, and clinical-trial laboratories worldwide.
- Ownership category
- akta.pro rank
Cytognos industry classification
Industry- Product category
- Clinical Flow Cytometry Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Flow Cytometry & Cellular Analysis Diagnostics (HLAHAAAF)
- akta.pro secondary industries
- Companion Diagnostics (CDx) & Precision Medicine IVD (HLAHAAAJ), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)
Keywords
Where Cytognos is headquartered
LocationHeadquarters
- HQ city
- Salamanca
- HQ country
- Spain
- HQ region
- Europe
Offices1 record
Markets served
Cytognos business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales, Infrastructure
Revenue model
- Reagents and Antibodies: Sale of flow cytometry reagents including single antibodies, multicolor cocktails, and ancillary reagents for clinical and research applications.
- Software Licenses: Licensing of Infinicyt™ flow cytometry analysis software with standalone and network license options, including database access and updates.
- CE-IVD Diagnostic Kits: Sale of CE-marked in vitro diagnostic products for clinical diagnostics including MRD assessment panels.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Pay-as-you-go | Standard product pricing based on official price list |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
Cytognos product offering
Product offeringCore offering
Cytognos designs, develops, manufactures, and commercializes CE-IVD clinical flow cytometry solutions. The portfolio combines standardized reagents (single antibodies, multicolor cocktails, ancillary reagents), the Infinicyt analysis software with EuroFlow reference databases, and disease-specific Next Generation Flow (NGF) solution kits for minimal residual disease (MRD) assessment in oncohematology, immunology, and clinical trial applications.
Product overview
Cytognos is a clinical flow cytometry company offering a unified Next Generation Flow (NGF) platform that combines reagents, software, and databases for standardized disease detection. The core portfolio includes: Infinicyt software for multiparametric flow cytometry analysis with automated gating and Compass classification; EuroFlow Databases providing reference populations for automated identification; and comprehensive reagent products including single antibodies, multicolor cocktails, and ancillary reagents. NGF Solutions span disease-specific applications including MRD assessment for acute leukemia, chronic lymphoproliferative disorders, plasma cell dyscrasias (multiple myeloma), and primary immunodeficiencies. The company also provides Timascan for monocyte subsets monitoring and supports clinical trials with standardized protocols.
Differentiator
Problem solved
Functional benefit
Brands
- Infinicyt™: Flow cytometry software for multiparametric analysis of flow cytometry data
- Next Generation Flow™
- EuroFlow™
Products and services
- Next Generation Flow (NGF) Solutions Standardized CE-IVD solution for clinical flow cytometry providing reagents, protocols, and software for minimal residual disease (MRD) assessment in oncohematology, immunology, and clinical trials. Targeted at clinical flow cytometry laboratories globally.
- Infinicyt Software Multiparametric flow cytometry analysis software with automated gating, compass classification, maturation tools, compensation management, and LIS integration via XML export. Supports FCS files and integrates with EuroFlow Databases for clinical flow cytometry laboratories.
- EuroFlow Databases Standardized reference databases for automated identification and classification of cell populations in flow cytometry samples, validated with BD FACSCanto II, BD FACSLyric, Omnicyt, and Thermo Fisher Attune NxT cytometer configurations.
- Single Antibodies Single antibody reagents for clinical and research flow cytometry applications, marketed under the Cytognos brand with proprietary dyes such as APC-750 and OC515.
- Multicolor Cocktails Pre-mixed antibody cocktails designed for multicolor flow cytometry panels and DNA/cell cycle analysis, sold to clinical and research flow cytometry laboratories.
- Ancillary Reagents Supporting reagents including the proprietary BulkLysis protocol/lysis solutions, buffers, and control materials used in Cytognos flow cytometry sample preparation workflows.
- NGF MRD Assessment Solution NGF solution for minimal residual disease assessment across hematological malignancies, marketed to oncohematology clinical laboratories.
- NGF Acute Leukemia (ALL) Solution NGF solution for diagnosis and MRD monitoring of acute lymphoblastic leukemia and acute myeloid leukemia, provided to oncohematology laboratories.
- NGF Chronic Lymphoproliferative Disorders (CLPD) Solution NGF solution for screening and diagnosis of chronic lymphoproliferative disorders including chronic lymphocytic leukemia (CLL), supplied to clinical immunology and hematology laboratories.
- NGF Plasma Cell Dyscrasias (PCD) Solution NGF solution for multiple myeloma MRD assessment using standardized 8-color panels, sold to oncohematology clinical flow cytometry laboratories.
- NGF Primary Immunodeficiencies (PID) Solution NGF solution featuring the PID orientation tube (PIDOT) for detection of lymphoid compartment defects in primary immunodeficiency diagnostics, compliant with ESID criteria.
- Timascan Monocyte Subsets Monitoring Solution NGF solution for monocyte subset analysis using the Timascan tube, provided to immunology and clinical research laboratories.
- Clinical Trials NGF Solutions Standardized NGF solutions with reagents and protocols tailored for clinical trial sample analysis and treatment response monitoring, supplied to clinical trial sponsors and contract research organizations.
Quantifiable outcome
- Detection sensitivity up to 10-6 level in MM MRD assessment
- +1 more outcomes
Companies that use Cytognos
Customer profileSegments3 records
Ideal customer profiles3 records
Cytognos technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration5 records
Feature4 records
Cytognos partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- BD (Becton, Dickinson and Company)coreCytognos and BD co-exhibit at major immunology conferences including ESID 2022. BD is mentioned as a distribution partner for Next Generation Flow solutions. BD FACSCanto™ II and BD FACSLyric™ are referenced as compatible instruments for Cytognos products.
- The European Scientific Foundation for Laboratory Hemato Oncology (ESLHO)coreCytognos holds license to commercialize EuroFlow™ standardized flow cytometry methodology and databases. EuroFlow™ is a joint development of European research consortium for standardized clinical flow cytometry. Cytognos products incorporate EuroFlow™ SOPs and reference databases.
Scale indicators1 record
Recent moves6 records
Expansion highlights6 records
Cytognos competitors and assessment
Company assessmentDirect peers
- BD Biosciences: BD Biosciences is a leading flow cytometry instrument and reagent provider (FACSCanto, FACSLyric). Cytognos lists BD as a distribution partner and compatible instrument vendor, making it the closest direct competitor and collaborator in clinical flow cytometry.
- Beckman Coulter Life Sciences: Beckman Coulter (part of Danaher) offers a comprehensive flow cytometry portfolio including Navios/FC500 instruments and antibody reagents. It is one of the primary clinical flow cytometry platforms Cytognos must validate against and competes with in MRD and immunology diagnostics.
- Cytek Biosciences: Cytek develops spectral flow cytometry instruments (Aurora, Northern Lights) and reagents. It is a next-generation direct competitor to Cytognos in clinical and research flow cytometry, particularly in immunophenotyping applications.
- Miltenyi Biotec: Miltenyi Biotec provides MACS flow cytometry reagents, instruments (MACSQuant), and cell analysis software. It competes with Cytognos in immunology and cell-therapy adjacent flow workflows, with similar breadth across reagents and instruments.
- BioLegend (PerkinElmer): BioLegend, now part of PerkinElmer/Revvity, is a major flow cytometry antibody and reagent supplier. Its broad catalog of single antibodies and multicolor cocktails directly competes with Cytognos's reagent product lines used by flow cytometry laboratories.
Broad incumbents
- Thermo Fisher Scientific (Invitrogen): Thermo Fisher, via Invitrogen and the Attune NxT instrument line, is a broad incumbent in flow cytometry reagents and instruments. Cytognos products are validated against the Attune NxT, indicating overlap and competition across the flow cytometry stack.
- Sysmex Corporation: Sysmex is a global leader in hematology diagnostics and has been expanding into clinical flow cytometry for hematological malignancies. It is a broader incumbent that competes at the lab-system level for MRD and leukemia/lymphoma immunophenotyping.
Emerging players
- Standard BioTools (formerly Fluidigm): Standard BioTools offers mass cytometry (CyTOF) and imaging mass cytometry for high-parameter cell analysis. It is an emerging alternative to traditional flow cytometry in immunology and immuno-oncology, partially overlapping with Cytognos's immunology diagnostics focus.
- 10x Genomics: 10x Genomics provides single-cell multi-omics platforms (Chromium, Xenium). While not classical flow cytometry, it competes for translational research and clinical trial budgets in cell characterization, an adjacent emerging modality to flow-based MRD.
Others
- Nexcelom Bioscience (PerkinElmer): Nexcelom (now part of PerkinElmer/Revvity) provides Cellometer automated cell counting and viability instruments. It is an adjacent enabling technology supplier in cell analysis workflows that complement flow cytometry in clinical and research labs.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key highlights7 records
Customer concentration
Cytognos social profiles
Digital presenceCytognos compliance and trust
Trust signalCompliance4 records
Cytognos financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cytognos leadership team
Management profileNumber of profiles
Profiles2 records
Cytognos funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cytognos M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cytognos
What does Cytognos do?
Cytognos designs, develops, manufactures, and commercializes CE-IVD clinical flow cytometry solutions. The portfolio combines standardized reagents (single antibodies, multicolor cocktails, ancillary reagents), the Infinicyt analysis software with EuroFlow reference databases, and disease-specific Next Generation Flow (NGF) solution kits for minimal residual disease (MRD) assessment in oncohematology, immunology, and clinical trial applications.
Is Cytognos a public or private company?
Cytognos is a private company. It is classified as unknown and is currently operating.
When was Cytognos founded?
Cytognos was founded in 1996. It employs 101 to 250 people.
Where is Cytognos based?
Cytognos is headquartered in Salamanca, Spain, in the Europe region.
How does Cytognos make money?
Three revenue lines are on record. Reagents and Antibodies are the primary driver. The others are software Licenses and CE-IVD Diagnostic Kits.
Who are Cytognos's main competitors?
Direct peers on record are BD Biosciences, Beckman Coulter Life Sciences, Cytek Biosciences, Miltenyi Biotec and BioLegend (PerkinElmer). Broad incumbents are Thermo Fisher Scientific (Invitrogen) and Sysmex Corporation. Emerging players are Standard BioTools (formerly Fluidigm) and 10x Genomics. Nexcelom Bioscience (PerkinElmer) is listed as an others.
Does Cytognos have an API?
No public API is recorded for Cytognos.
What industry is Cytognos in?
Cytognos's product category is Clinical Flow Cytometry Diagnostics. Its primary akta.pro industry code is HLAHAAAF, Flow Cytometry & Cellular Analysis Diagnostics, with a secondary code of HLAHAAAJ, Companion Diagnostics (CDx) & Precision Medicine IVD. Its NAICS code is 325413 and its SIC code is 2835.